Table 1 Overall patient characteristics.
Total (%) N = 310 | TKI plus bevacizumab (%) N = 43 | TKI alone (%) N = 267 | p value | |
|---|---|---|---|---|
Age (mean ± SD) | 60.4 ± 9.8 | 71.2 ± 12.1 | < 0.001 | |
Age ≥ 65 | 208 (67.1) | 15 (34.9) | 193 (72.3) | < 0.001 |
ECOGPS 0–1 | 232 (74.8) | 38 (88.4) | 194 (72.7) | 0.036 |
Gender | ||||
Male | 105 (33.9) | 14 (32.6) | 237 (34.1) | 1.000 |
Current/ex-smoker | 73 (23.5) | 11 (25.6) | 62 (23.2) | 0.703 |
Histology | ||||
Adenocarcinoma | 307 (99.0) | 43 (100.0) | 264 (98.9) | 1.000 |
Others | 3 (1.0) | 0 | 3 (1.1) | |
EGFR mutation | ||||
L858R | 185 (59.7) | 23 (53.5) | 162 (60.7) | 0.405 |
19deletion | 125 (40.3) | 20 (46.5) | 105 (39.3) | |
Disease stage | ||||
III | 18 (5.6) | 1 (2.3) | 17 (6.4) | 0.485 |
IV | 292 (94.4) | 42 (97.7) | 250 (93.6) | |
Site of metastasis | ||||
Brain | 137 (44.2) | 24 (55.8) | 113 (42.3) | 0.140 |
Liver | 40 (12.6) | 7 (16.3) | 33 (12.4) | 0.469 |
EGFR TKI administered | ||||
Gefitinib | 124 (40.0) | 4 (9.3) | 120 (44.9) | < 0.001 |
Erlotinib | 186 (60.0) | 39 (90.7) | 147 (55.1) | |
